A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma

Anamarija M. Perry, Teresa M. Cardesa-Salzmann, Paul N. Meyer, Luis Colomo, Lynette M. Smith, Kai Fu, Timothy C. Greiner, Jan Delabie, Randy D. Gascoyne, Lisa Rimsza, Elaine S. Jaffe, German Ott, Andreas Rosenwald, Rita M. Braziel, Raymond Tubbs, James R. Cook, Louis M. Staudt, Joseph M. Connors, Laurie H. Sehn, Julie M. VoseArmando Loṕez-Guillermo, Elias Campo, Wing C. Chan, Dennis D. Weisenburger

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


Biologic factors that predict the survival of patients with a diffuse large B-cell lymphoma, such as cell of origin and stromal signatures, have been discovered by gene expression profiling. We attempted to simulate these gene expression profiling findings and create a new biologic prognostic model based on immunohistochemistry. We studied 199 patients (125 in the training set, 74 in the validation set) with de novo diffuse large B-cell lymphoma treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like therapies, and immunohistochemical stains were performed on paraffin-embedded tissue microarrays. In the model, 1 point was awarded for each adverse prognostic factor: nongerminal center B cell-like subtype, SPARC (secreted protein, acidic, and rich in cysteine) < 5%, and microvascular density quartile 4. The model using these 3 biologic markers was highly predictive of overall survival and event-free survival in multivariate analysis after adjusting for the International Prognostic Index in both the training and validation sets. This new model delineates 2 groups of patients, 1 with a low biologic score (0-1) and good survival and the other with a high score (2-3) and poor survival. This new biologic prognostic model could be used with the International Prognostic Index to stratify patients for novel or risk-adapted therapies.

Original languageEnglish (US)
Pages (from-to)2290-2296
Number of pages7
Issue number11
StatePublished - Sep 13 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this